Shelly W. McQuaid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shelly W. McQuaid has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
1 shared publication Alex Sickler
1 shared publication- Allison P. Heath
Children's Hospital of Philadelphia, Philadelphia, PA
1 shared publication - Ammar S. Naqvi
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia, Philadelphia, USA
1 shared publication - Angela J. Waanders
Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine Chicago Illinois USA
1 shared publication - Antonia Chroni
Institute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, PA 19122, USA
1 shared publication
Latest Publications
- Open Access
- 8 March 2025
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (2) , e70008
Navigating sexual orientation and gender identity data privacy concerns in United States genetics practices
- 8 March 2025
- Published by Wiley in Journal of Genetic Counseling
- Vol. 34 (2) , e70008
Open AccessNavigating sexual orientation and gender identity data privacy concerns in United States genetics practices
- Open Access
Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors
The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.
Open AccessGermline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors
The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.